Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results

Blood

Volumn 119, Issue 26, 2012, Pages 6373-6378

  Khouri, Issa F ^a   Saliba, Rima M ^a   Erwin, William D ^a   Samuels, Barry I ^a   Korbling, Martin ^a   Medeiros, L Jeffrey ^a   Valverde, Rosamar ^a   Alousi, Amin M ^a   Anderlini, Paolo ^a   Bashir, Qaiser ^a   Ciurea, Stefan ^a   Gulbis, Alison M ^a   De Lima, Marcos ^a   Hosing, Chitra ^a   Kebriaei, Partow ^a   Popat, Uday R ^a   Fowler, Nathan ^a   Neelapu, Sattva S ^a   Samaniego, Felipe ^a   Champlin, Richard E ^a   Macapinlac, Homer A ^a   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE; IBRITUMOMAB TIUXETAN; INDIUM 111; RITUXIMAB; YTTRIUM 90;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CHIMERA; CLINICAL ARTICLE; CONTROLLED STUDY; ENGRAFTMENT; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; GRAFT VERSUS HOST REACTION; HUMAN; MALE; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84863506635     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-03-417808     Document Type: Article

References (23)

1. van Oers MHJ, Van Glabbeke M, Giurgea L, et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol. 2010;28(17):2853-2858.
2. Gordon LI, Molina A, Witzig T, et al. Durable responses after ibritumumab-tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of phase 1/2 study. Blood. 2004;103(12):4429-4431. (Pubitemid 38745967)
3. Peniket AJ, Ruiz de Elvira MC, Taghipour G, et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant. 2003;31(8):667-678.
4. Hosing C, Saliba RM, McLaughlin P, et al. Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin's lymphoma. Ann Oncol. 2003;14(5):737-744. (Pubitemid 36621774)
5. Khouri IF, McLaughlin P, Saliba RM, et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood. 2008;111(12):5530-5536.
6. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritimumab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol. 2002;20(10):2453-2463. (Pubitemid 34525730)
7. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma: NCI Sponsored International Working Group. J Clin Oncol. 1999;17(4):1244-1253. (Pubitemid 29162950)
8. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579-586. (Pubitemid 350002966)
9. Barrington SF, Qian W, Somer EJ, et al. Concordance between four European centers of PET reporting criteria designed for use in multicenter trials in Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging. 2010;37(10):1824-1833.
10. Witzig TE, White CA, Gordon LI, et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol. 2003;21(7):1263-1270. (Pubitemid 46606402)
11. Khouri IF, Lee MS, Saliba RM, et al. Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival. Exp Hematol. 2004;32(1):28-35. (Pubitemid 38064398)
12. Przepiorka D, Weisdorf D, Martin P, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15(6):825-828.
13. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: 1. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945-956. (Pubitemid 41754712)
14. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457-481.
15. Kalbfleish JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York, NY: John Wiley; 1980;23(21):3397-3398.
16. Khouri IF, Saliba RM, Hosing C, et al. Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. J Clin Oncol. 2005;23(10):2240-2247. (Pubitemid 46218716)
17. Khouri IF, Bassett R, Poindexter N, et al. Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia: long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcome. Cancer. 2011;117(20):4679-4688.
18. Shea TC, Johnston J, Walsh W, et al. Reduced intensity allogeneic transplantation provides high disease-free and overall survival in patients (pts) with advanced idolent NHL and CLL: CALGB 109901 [abstract]. Blood (ASH Annual Meeting Abstracts). 2007;110:486a.
19. Tomblyn MR, Ewell M, Beredeson C, et al. Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response. Biol Blood Marrow Transplant. 2011;17(7):1051-1057.
20. Piñana JL, Martino R, Gayoso J, et al. Reduced-intensity conditioning HLA-identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials. Haematologica. 2010;95(7):1176-1182.
21. Zipp L, Saliba RM, Valverde R, et al. Mature results of BEAM/high-dose rituximab vs BEAM/yttrium-90 ibritumomab tiuxetan (Zevalin) and autologous stem cell transplantation (ASCT) for relapsed CD20+ follicular and diffuse large b-cell lymphoma: survival outcomes and risk of secondary malignancies [abstract]. Blood (ASH Annual Meeting Abstracts). 2011;118(21):874a.
22. Bethge WA, Lange T, Meisner C, et al. Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase 2 study. Blood. 2010;116(10):1795-1802.
23. Gopal AK, Guthrie KA, Rajendran J, et al. 90Y-ibritumumab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma. Blood. 2011;118(4):1132-1139.